MedTrace Logo

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-04-23

No results posted yet for this study

Summary

This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.

Conditions

  • Hiv
  • HIV Infections
  • Immune Deficiency

Interventions

BIOLOGICAL

Haploidentical Natural Killer (NK) Cells

infusion with N-803 activated NK cells

Sponsors & Collaborators

Principal Investigators

  • Timothy Schacker, MD · University of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-04-01
Completion
2021-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899480 on ClinicalTrials.gov